A detailed history of Bank Of Montreal transactions in Apellis Pharmaceuticals, Inc. stock. As of the latest transaction made, Bank Of Montreal holds 132,318 shares of APLS stock, worth $3.81 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
132,318
Previous 132,937 0.47%
Holding current value
$3.81 Million
Previous $7.81 Million 35.05%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$38.07 - $59.71 $23,565 - $36,960
-619 Reduced 0.47%
132,318 $5.08 Million
Q1 2024

May 13, 2024

SELL
$55.39 - $72.47 $18.7 Million - $24.4 Million
-336,947 Reduced 71.71%
132,937 $7.81 Million
Q4 2023

Feb 08, 2024

BUY
$37.14 - $64.82 $1.41 Million - $2.46 Million
37,911 Added 8.78%
469,884 $28.1 Million
Q3 2023

Nov 01, 2023

BUY
$23.65 - $89.22 $8.37 Million - $31.6 Million
354,047 Added 454.34%
431,973 $16.4 Million
Q2 2023

Aug 02, 2023

SELL
$76.68 - $93.31 $1.76 Million - $2.15 Million
-23,005 Reduced 22.79%
77,926 $7.1 Million
Q1 2023

Jun 13, 2024

BUY
$46.59 - $66.96 $3.43 Million - $4.93 Million
73,611 Added 55.37%
206,548 $13.6 Million
Q4 2022

Feb 01, 2023

SELL
$43.24 - $61.04 $1.23 Million - $1.73 Million
-28,408 Reduced 21.96%
100,931 $5.22 Million
Q3 2022

Nov 10, 2022

SELL
$44.76 - $69.66 $1.74 Million - $2.7 Million
-38,786 Reduced 23.07%
129,339 $8.92 Million
Q2 2022

Aug 11, 2022

BUY
$35.07 - $59.21 $631 - $1,065
18 Added 0.01%
168,125 $7.81 Million
Q1 2022

May 12, 2022

SELL
$35.46 - $54.12 $410,414 - $626,384
-11,574 Reduced 6.44%
168,107 $8.33 Million
Q4 2021

Feb 11, 2022

SELL
$30.74 - $49.16 $2.27 Million - $3.63 Million
-73,847 Reduced 29.13%
179,681 $8.77 Million
Q3 2021

Nov 12, 2021

SELL
$31.4 - $69.84 $30,301 - $67,395
-965 Reduced 0.38%
253,528 $8.61 Million
Q2 2021

Aug 12, 2021

BUY
$40.9 - $64.9 $10.4 Million - $16.5 Million
254,493 New
254,493 $16.3 Million

Others Institutions Holding APLS

About Apellis Pharmaceuticals, Inc.


  • Ticker APLS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 109,865,000
  • Market Cap $3.17B
  • Description
  • Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...
More about APLS
Track This Portfolio

Track Bank Of Montreal Portfolio

Follow Bank Of Montreal and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of Montreal , based on Form 13F filings with the SEC.

News

Stay updated on Bank Of Montreal with notifications on news.